Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.
23 Apr 2018
Long‐term treatment with perampanel in the adjunctive setting appears to provide improved seizure control without raising new safety/tolerability signals in patients with epilepsy, particularly those with secondarily generalized seizures at baseline, according to the results of an open-label extension of phase III trials.

Medication administration causes feeding tube obstruction

07 Aug 2019

The combination of metformin, nystatin, linagliptin, rivaroxaban and a high-protein diet is the main cause of nasoenteral tube obstruction, with corresponding odds ratios of 2.0, 3.1, 4.3, 2.4 and 1.9, according to a recent study.

Of the 1,170 patients included in the analysis, 1,084 received enteral nutrition and medication through the feeding tube, and 86 received medication alone.

Obstruction rates were 4 percent and 8 percent for up to 40 days of observation and for the total observation time, respectively. The time for obstruction of 10 percent of the tubes was 16 days in rivaroxaban users, 19 days in linagliptin users, 20 days in metformin users and 28 days in nystatin users.

“Overall, proper tube care and strict compliance with tubal drug delivery guidelines can result in low tube obstruction rates,” the investigators said.

This retrospective cohort study included patients aged 18 years (median age, 79 years; 58 percent men) who were hospitalized at Sírio-Libanês Hospital in São Paulo, Brazil, between January 2015 and October 2017, and who were undergoing enteral nutrition therapy delivered using an infusion pump through a nasogastric or nasoenteral tube.

The following variables were investigated as potential causes of feeding tube obstruction: administration of medication through the tube, type of diet and use of symbiotics.

“Obstruction of the nasoenteral tube is one of the complications of enteral nutrition therapy, and its causes and frequency of occurrence are not well understood,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.
23 Apr 2018
Long‐term treatment with perampanel in the adjunctive setting appears to provide improved seizure control without raising new safety/tolerability signals in patients with epilepsy, particularly those with secondarily generalized seizures at baseline, according to the results of an open-label extension of phase III trials.